CYPRESS BIOSCIENCE (NASDAQ:CYPB)
5.53
0.01 (0.18%)
| CYPRESS BIOSCIENCE (NASDAQ:CYPB) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $5.54 | 52 Week High | $10.10 | ||
| Open | $5.55 | 52 Week Low | $4.98 | ||
| Day High | $5.69 | P/E | N/A | ||
| Day Low | $5.51 | EPS | $-0.80 | ||
| Volume | 537,571 | ||||
| More CYPB Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| FRX | 4 | BAC | 2 |
| SAY | 2 | CLC | 2 |
| TRMB | 2 | JPM | 2 |
| MI | 2 | ASEI | 1 |
| DTE | 1 | HSY | 1 |
| ROC | 1 | NUAN | 1 |
Entities who have mentioned CYPB
- Banc of America | View Related Stories »
- Citi | View Related Stories »
- JPMorgan | View Related Stories »
- Matrix USA | View Related Stories »
- Dividend | View Related Stories »
- Carl Icahn | View Related Stories »
- Cerberus Capital | View Related Stories »
- Goldman Sachs | View Related Stories »
- Morgan Stanley | View Related Stories »
- Goldman Sachs Conviction Buy List | View Related Stories »
- JMP Securities | View Related Stories »
- EIM Group | View Related Stories »
- Jefferies & Co | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Credit Suisse | View Related Stories »
- Twitter | View Related Stories »
- Piper Jaffray | View Related Stories »
- Merrill Lynch | View Related Stories »
- Warburg Pincus | View Related Stories »
- Collins Stewart | View Related Stories »
- Steve Jobs | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Bankruptcy | View Related Stories »
View All Major News StreetInsider.com Major News for CYPB
- Cypress Bioscience (CYPB) Reports Q1 Loss of $0.24
- Cypress Bioscience (CYPB) Reports A Wider Than Expected Loss
- Forest Labs (FRX) and Cypress Bioscience (CYPB) Announce FDA Approval For Savella
View All ReportsStreetInsider.com Reports on CYPB
- Oppenheimer Upgrades Cypress Bioscience (CYPB) to Outperform
- Forest Lab (FRX) and Cypress Bio (CYPB) Announce Savella Phase III Results
- Cypress Bioscience (CYPB) Reports Q1 Loss of $0.24
- Morning Movers 3/25: CBG, BIOD, ACAS, BBI, AMD Higher; DRYS, SOLF, STZ, CYPB, DSW Lower
- Oppenheimer Downgrades Cypress Bioscience (CYPB) to Perform
View All Press ReleasesCompany Press Releases on CYPB
- Trading Outlook for Hard To Treat Diseases Inc. Issued by InvestorSoup.com
- Cypress Bioscience Announces Third Quarter 2009 Financial Results
- Cypress Bioscience, Inc. to Present at Oppenheimer 20th Annual Healthcare Conference
- Forest Laboratories and Cypress Bioscience Announce Study Shows Patients Treated with Savella Experience Improvements in Pain and Physical Function
StreetInsider Reports on CYPB by Category
View All BlogsBlogs on CYPB
- Cypress Bioscience: Investing in Pain
- FDA, Clinical Trial Calendar Updates: Actelion, Merck Discontinue Partnership
- 9 Possible Pharma Deals for 2009
- 4 Drug Stocks Trading Above Moving Averages
- 3 Top and Bottom Market Sectors for This Week
View All FilingsSEC Filings on CYPB
- Form 4 Walsh Michael For: Nov 09
- Form 10-Q CYPRESS BIOSCIENCE INC For: Sep 30
- Form 8-K CYPRESS BIOSCIENCE INC For: Nov 09
Comments on CYPB
No comments are currently available.
